Gut

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER


[Advanced]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spiller, R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Spiller, R.
Topic Collections
Right arrowRelevant Articles
Gut 2005;54:1
© 2005 by BMJ Publishing Group Ltd & British Society of Gastroenterology

Digest

Robin Spiller, Editor

The first 150 words of the full text of this article appear below.


Importance of underlying mesenchyme in the development of intestinal metaplasia and gastric cancer
The atrophy–intestinal metaplasia–gastric cancer sequence following H pylori infection is well recognised but the mechanisms are poorly understood. There has recently been great interest in the intestinal specific transcription factor Cdx2, which is expressed in human gastric mucosa with intestinal metaplasia. Over expression of Cdx2 in transgenic mice causes complete intestinal metaplasia of the gastric mucosa and subsequent development of gastric polyps and carcinoma. It is well known that the basement membrane derived from intestinal mesenchyme stimulates intestinal cell differentiation, but the role of mesenchyme in controlling intestinal metaplasia is uncertain. The present study examined the stomach of Cdx2 transgenic mice for the presence of the pericryptal fibroblasts (PCFs), which are normally only found in the intestine. Although there were no PCFs in the normal stomach, they were clearly detected when intestinal metaplasia had developed but disappeared as gastric cancer developed. Similar changes were noted in intestinal metaplasia and gastric . . . [Full text of this article]


Relevant Articles

Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study
E L Thomas, G Hamilton, N Patel, R O’Dwyer, C J Doré, R D Goldin, J D Bell, and S D Taylor-Robinson
Gut 2005 54: 122-127. [Abstract] [Full Text] [PDF]

Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C
A K P Lim, S D Taylor-Robinson, N Patel, R J Eckersley, R D Goldin, G Hamilton, G R Foster, H C Thomas, D O Cosgrove, and M J K Blomley
Gut 2005 54: 128-133. [Abstract] [Full Text] [PDF]

Pericryptal fibroblast sheath in intestinal metaplasia and gastric carcinoma
H Mutoh, S Sakurai, K Satoh, H Osawa, T Tomiyama, H Kita, T Yoshida, K Tamada, H Yamamoto, N Isoda, K Ido, and K Sugano
Gut 2005 54: 33-39. [Abstract] [Full Text] [PDF]

CD4+CD45RBHi T cell transfer induced colitis in mice is accompanied by osteopenia which is treatable with recombinant human osteoprotegerin
F R Byrne, S Morony, K Warmington, Z Geng, H L Brown, S A Flores, M Fiorino, S L Yin, D Hill, V Porkess, D Duryea, J K Pretorius, S Adamu, R Manuokian, D M Danilenko, I Sarosi, D L Lacey, P J Kostenuik, and G Senaldi
Gut 2005 54: 78-86. [Abstract] [Full Text] [PDF]





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 BMJ Publishing Group Ltd & British Society of Gastroenterology